Kaleidoscope.bio

The amazing thing about biotech is that each company is fighting to commercialize a novel piece of science. But most biotechs are less unique than they seem. Put differently: most biotechs have for more in common with each other than they perhaps think (or care to admit). While the underlying technology or scientific advancement is likely very special and often one-of-a-kind, most of the surrounding 'tissue' is shared across the industry. Design cycle runs, target-indication evidence, TPPs, regulatory, production/scaling, talent recruitment, major fundraising milestones -- these are a few examples of challenges that every biotech faces. And when you group companies by e.g. modality, these challenges are near-identical. Yet so many biotechs (consciously or subconsciously) make the mistake of assuming that novel science = novel everything else, and they overextend how many things they do in-house. What ends up happening is that many companies recreate the wheel, when it comes to the processes or tools that they use. They burn huge amounts of valuable time, human resource, and cash, instead of focusing this on their most differentiated aspect: their science. The industry as a whole can stand to benefit a lot from building on top of things, be it past learnings, partnerships, or industry standards. And, of course, more open discourse around the very real challenges of successfully going from a nugget of an idea, through novel R&D, and finally to market. We published a brief piece about this, which you can read here:

The amazing thing about biotech is that each company is fighting to commercialize a novel piece of science. But most biotechs are less unique than they seem. Put differently: most biotechs have for more in common with each other than they perhaps think (or care to admit). While the underlying technology or scientific advancement is likely very special and often one-of-a-kind, most of the surrounding 'tissue' is shared across the industry. Design cycle runs, target-indication evidence, TPPs, regulatory, production/scaling, talent recruitment, major fundraising milestones -- these are a few examples of challenges that every biotech faces. And when you group companies by e.g. modality, these challenges are near-identical. Yet so many biotechs (consciously or subconsciously) make the mistake of assuming that novel science = novel everything else, and they overextend how many things they do in-house. What ends up happening is that many companies recreate the wheel, when it comes to the processes or tools that they use. They burn huge amounts of valuable time, human resource, and cash, instead of focusing this on their most differentiated aspect: their science. The industry as a whole can stand to benefit a lot from building on top of things, be it past learnings, partnerships, or industry standards. And, of course, more open discourse around the very real challenges of successfully going from a nugget of an idea, through novel R&D, and finally to market. We published a brief piece about this, which you can read here:

Second day at BiotechX in Philadelphia! If you’re in town, come by the poster area to chat!

We’re growing the team at Kaleidoscope.bio! Lots happening, lots more to come -- we’re adding a few key people to help make more magic happen, faster. If you’re looking to do meaningful work, are excited about the rapidly evolving intersection of software technology and R&D (biotech and beyond), and think you could be a good fit for one of the roles below, let us know! We’re an ambitious, focused, and experienced (remote-first) team, applying best-in-class engineering and design principles to the challenges of modern R&D. Questions like how can we help bring about a world where R&D organizations can make confident, data-savvy decisions? How can we assist teams in focusing attention on the most promising directions, quickly? How can we play a role in getting more therapeutics, diagnostics, and technologies on the market and in the hands of the populations that need them the most? For more on us, check out our website: https://lnkd.in/eyrUp9Pj For more on the roles, check out the links below. The applications themselves are referenced in each of the pages, as well as in the comments below. Account Executive (AE): https://lnkd.in/etTyFRKr Scientific Customer Success Manager (Scientific CSM): https://lnkd.in/etwzMetG Software Engineer (SWE): https://lnkd.in/eTQ7gvfw

How do world class R&D teams manage their operations and deliver the next generation of therapies? The missing keys are here: https://kaleidoscope.bio

ICYMI 👀 Psivant's state of the art computational platform uses quantum physics-based simulations, bespoke AI/ML methods, and advanced super-computing to identify promising molecules for challenging disease targets. Swipe for a peak at how the Psivant team uses Kaleidoscope to drive weekly prioritization decisions, manage CRO partners in real time, and ultimately save two months a year in operational efficiency. Full case study here: https://lnkd.in/gXRhYVmh

Reviewing compound hit and lead data is such a core part of a biotech’s workflow… so why is it such a painful challenge? Hours and hours of manual work, every week, across numerous functions and seniorities. At first glance, the problem seems simple. As Jesse Johnson described in a May issue of his Scaling Biotech newsletter: “a hit dashboard is just a table, right?”. But, as he goes on to explain, the hard part isn’t making a table. It’s all the work that goes into getting the right data and context into the table. Everything from where the data is (and how to find it), to the question of how to capture relevant experimental context or represent multiple experimental iterations — all of this introduces significant complexity. The end result is people (often very senior people) have to spend heaps of hours, manually constructing these tables. And not infrequently — reviewing compound performance can be a weekly event. Not only is this a massive waste of time, but the process leaves huge gaps for expensive errors to occur: out of date information, unverifiable results, missed context that could sway a major pipeline decision. Kaleidoscope comparison dashboards are our way to tackle this exact problem. By leveraging Kaleidoscope, biotechs are able to spin up compound leaderboards on the fly, to compare any combination of assets, sets, and parameters that they care about. And because Kaleidoscope connects directly into the other tools and data stores that a team uses, these candidate dashboards can distill data down into a digestible format, while preserving any critical context that needs to be factored into the decision-making. The net result? A lean, efficient, and robust engine for driving reliable and fast decision-making, based on your latest data and most pressing goals. Interested in finding out more? Check us out at: https://lnkd.in/eRrWcPwt

Zooming out 🔭 or drilling in 🔍? See all your ongoing tasks and experiments from whatever angle you need with Kaleidoscope.bio’s gantt view. https://lnkd.in/gRaUXM4t #biotech #sciencesoftware #pharma #sciencetools #drugdevelopment #cdmo #therapeutics

This week's conversation with Bogdan Knezevic, founder of Kaleidoscope.bio, was so much fun! We talked about how companies can streamline operations and save money (and we love saving money!) Simply put, most organizations do not clearly define goals and track progress toward those goals. In biopharma, that means tracking data points and avoiding shiny object syndrome. Check out this episode to learn some simple tactics to stay on track and keep the organization lean. #podcast #biotechnologypodcast #biotechstartup #operationalefficiency #projectmanagement

Hi friends! 👋 We're excited to be growing our team at Kaleidoscope.bio and are looking for a talented Software Engineer to join our remote-first company. If you're passionate about advancing scientific research, thrive in a collaborative and supportive environment, and want to make an impact at a fast-growing startup, we’d love to hear from you! Know someone who would be a great fit? Please share this with them! 🚀 Details & application link in comments below 👇